Eyenovia, Inc. (NASDAQ:EYEN) Major Shareholder Purchases $98,000.00 in Stock

Eyenovia, Inc. (NASDAQ:EYEN) major shareholder Stuart M. Grant bought 100,000 shares of the company’s stock in a transaction dated Thursday, March 28th. The stock was bought at an average cost of $0.98 per share, for a total transaction of $98,000.00. Following the acquisition, the insider now owns 5,430,715 shares of the company’s stock, valued at approximately $5,322,100.70. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Eyenovia Price Performance

NASDAQ EYEN remained flat at $0.99 during trading hours on Thursday. The company had a trading volume of 786,734 shares, compared to its average volume of 927,150. The business’s fifty day moving average is $1.69 and its 200 day moving average is $1.61. The stock has a market cap of $46.73 million, a P/E ratio of -1.49 and a beta of 1.72. The company has a debt-to-equity ratio of 1.00, a current ratio of 2.17 and a quick ratio of 2.16. Eyenovia, Inc. has a 52-week low of $0.92 and a 52-week high of $5.85.

Eyenovia (NASDAQ:EYEN) last issued its quarterly earnings data on Monday, March 18th. The company reported ($0.17) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.17). During the same period last year, the business posted ($0.17) EPS. On average, equities analysts anticipate that Eyenovia, Inc. will post -0.91 EPS for the current year.

Hedge Funds Weigh In On Eyenovia

Several institutional investors have recently made changes to their positions in the stock. Armistice Capital LLC increased its holdings in shares of Eyenovia by 41.8% during the fourth quarter. Armistice Capital LLC now owns 4,378,000 shares of the company’s stock valued at $9,106,000 after purchasing an additional 1,290,979 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Eyenovia by 4.5% during the fourth quarter. Vanguard Group Inc. now owns 1,429,577 shares of the company’s stock valued at $2,974,000 after purchasing an additional 61,732 shares during the last quarter. BlackRock Inc. raised its stake in Eyenovia by 1,704.3% during the 2nd quarter. BlackRock Inc. now owns 1,334,953 shares of the company’s stock valued at $3,164,000 after purchasing an additional 1,260,966 shares during the period. Geode Capital Management LLC increased its stake in Eyenovia by 113.6% in the 2nd quarter. Geode Capital Management LLC now owns 555,479 shares of the company’s stock valued at $1,316,000 after buying an additional 295,412 shares during the period. Finally, State Street Corp grew its stake in Eyenovia by 433.5% in the second quarter. State Street Corp now owns 442,382 shares of the company’s stock valued at $1,048,000 after purchasing an additional 359,465 shares in the last quarter. 25.84% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $12.00 price objective on shares of Eyenovia in a research report on Tuesday, March 19th.

About Eyenovia

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.